LBA20: Sacituzumab govitecan significantly prolongs PFS versus chemotherapy in advanced triple-negative breast cancer
Results from a late-breaking abstract presented at ESMO 2025 suggest that sacituzumab govitecan may establish a new standard of care for patients with advanced triple-negative breast cancer (TNBC).
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
